Heartland Advisors Inc. Purchases 175,383 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Financial Advisors

Heartland Advisors Inc. increased its shares in AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) by 40.2% in the fourth quarter, according to its latest filings with the U.S. Securities and Exchange Commission (SEC). The institutional investor owned his 611,722 shares of the medical device supplier’s shares after he purchased an additional 175,383 shares during the quarter. Heartland Advisors Inc. owned approximately 1.56% of his AngioDynamics worth $8,423,000 at the end of the most recent reporting period.

Several other big investors have also recently changed positions in the company. CWM LLC increased his AngioDynamics shareholding by 1,048.0% in the fourth quarter. CWM LLC now owns 2,032 shares of the medical device supplier worth $28,000 after he purchased an additional 1,855 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in his AngioDynamics worth about $36,000 in the first quarter. Captrust Financial Advisors raised a 95.1% stake in his AngioDynamics in the first quarter. Captrust Financial Advisors now owns 2,883 shares in the medical device supplier worth $62,000 after he purchased an additional 1,405 shares during the previous quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holding of AngioDynamics shares by 23.9% in the fourth quarter. Zurich Kantonalbank Zurich Kantonalbank now owns 6,614 shares in the medical device supplier worth $91,000 after purchasing an additional 1,277 shares in him last quarter. Finally, Tower Research Capital LLC TRC boosted its AngioDynamics stock position by 187.1% in the third quarter. Tower Research Capital LLC TRC now owns 4,442 shares of the medical device supplier worth $91,000 after purchasing an additional 2,895 shares during the previous quarter. Currently 94.94% of the shares are owned by institutional investors and hedge funds.

AngioDynamics trading down 2.2%

ANGO shares opened at $8.48 on Friday. His one-year low for AngioDynamics, Inc. is $8.18 and his one-year high is $24.74. The stock has a 50-day simple moving average of $10.55 and a 200-day simple moving average of $12.40. The company has a debt to equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.28.

AngioDynamics (NASDAQ:ANGO – Get Rating) last released quarterly earnings data on Thursday, March 30. Medical device suppliers reported ($0.03) EPS for the quarter and missed the consensus estimate of ($0.01) by ($0.02). The company made $80.7 million in revenue for the quarter, compared to consensus expectations of $83.2 million. AngioDynamics’ return on equity was 0.71% and net profit margin was 11.13%. Business revenue increased by 9.1% year-on-year. During the same period last year, the company posted his EPS of $0.03. On average, equity analysts expect AngioDynamics, Inc. to post -0.05 EPS this year.

Analyst upgrades and downgrades

Several analysts recently issued reports on ANGO stocks. StockNews.com mentioned he shares in AngioDynamics in a research note on Thursday, March 16th. They issued a “pending” rating to the company. Raymond James downgraded AngioDynamics shares from a ‘strong buy’ rating to an ‘outperform’ rating in a research report on Monday, April 17, and lowered his price target from $14.00 to $13.00. rice field.

AngioDynamics profile

(get rating)

AngioDynamics, Inc. is a medical device company engaged in the development, manufacture and sale of medical devices for vascular access, surgery, peripheral vascular disease and oncology. We provide ablation systems, fluid management systems, vascular access, angiography, and drainage. Thrombolytic and intravenous products.

Recommended story

Want to know which other hedge funds hold ANGO? Visit HoldingsChannel.com to get the latest AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) 13F filings and insider trading.

AngioDynamics (NASDAQ:ANGO) Quarterly Institutional Ownership

This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.

Listen to this before you consider AngioDynamics.

MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified 5 stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and AngioDynamics wasn’t on the list .

AngioDynamics is currently rated as a ‘buy’ among analysts, but the top rated analysts believe these five stocks are better buys.

See 5 stocks here

10 best cheap stocks to buy right now

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *